Compare IDEXX Laboratories, Inc. (IDXX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Thomson Reuters Corp — how do they compare? IDEXX Laboratories, Inc. trades at $572.01 (market cap $44.95B), while Thomson Reuters Corp trades at $104.52 (market cap $44.45B). The key difference: IDEXX Laboratories, Inc. and Thomson Reuters Corp are close in size by market cap, and Thomson Reuters Corp pays a 2.55% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TRI | |
|---|---|---|
Market Cap | $44.95B | $44.45B |
Sector | Health | Industrials |
52-Week High | $766.68 | $178.77 |
52-Week Low | $526.44 | $76.55 |
Enterprise Value | $45.85B | $47.07B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Thomson Reuters (TRI) trades at $102.61, down 1.68% today, with a bullish technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Valuation ratios include a P/E of 27.61 and a net income margin of 21.22%. Recent news highlights AI-driven growth and a joint venture with KKR.
Outlook is positive with analyst consensus favoring a Buy rating and a $102.33 price target. Key opportunities include recurring revenue growth and AI adoption, while risks involve execution of strategic initiatives and competitive pressures in the legal and tax sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
